AstraZeneca’s Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for heart failure (HF), or urgent HF visits in adults with symptomatic chronic HF. The drug was previously approved in China but was limited to HF patients with reduced ejection fraction (HFrEF). The approval by China’s National Medical Products […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!